Clinical Outcome after Trimipramine in Patients with Delusional Depression - a Pilot Study

Abstract

The treatment of delusional depression is a major challenge in psychopharmacology. Hypothalamic-pituitary-adrenocortical (HPA) overdrive may contribute, via increased dopaminergic activity, to the pathophysiology of the disorder. Trimipramine appears to be an interesting potential candidate, since it is an atypical antidepressant that is known to inhibit HPA activity. In a four-week open trial we investigated its effects in 15 inpatients with delusional depression. The dosage was increased within 7 days up to 300 - 400 mg/d and was then maintained for three weeks. Psychometric assessments and safety monitoring were conducted weekly. Assessment of the HPA activity was achieved by a combined dexamethasone suppression/corticotropin-releasing hormone stimulation (Dex/CRH) test before and after four weeks of treatment. Therapeutic response was defined as a decrease in the HAMD-score of at least 50 %. Eight out of 13 completers were rated as responders. Therapeutic response was associated with L, D-trimipramine concentrations higher than 160 ng/ml. Intent-to-treat analysis showed significant improvement in psychometric variables. Despite the high dosage, the substance was generally well tolerated, with the exception of one patient who suffered from a hypotensive reaction. Mean ± SD concentration of L-trimipramine and D-trimipramine were 138 ± 61 ng/ml and 119 ± 50 ng/ml at a final dose of 346 ± 50 mg/d. The ACTH and cortisol area under the curve in the Dex/CRH tests decreased significantly, reflecting a decrease of activity in the HPA system. We suggest that the clinical use of high-dose trimipramine in delusional depression seems to be a promising treatment strategy.

References

• 1 Bender S, Olbrich H, Hornstein C, Schöne W, Falkai P. Antipsychotic efficacy of the antidepressant trimipramine: double-blind comparison with the phenothiazine perazine.  Biol Psychiatry. 1997;  42 231S
• 2 Berger M, Gastpar M. Trimipramine: a challenge to current concepts on antidepressives.  Eur Arch Psychiatry Clin Neurosci. 1996;  246 235-239
• 3 Chan C H, Janicak P G, Davis J M, Altman E, Andriukaitis S, Hedeker D. Response of psychotic and nonpsychotic depressed patients to tricyclic antidepressants.  J Clin Psychiat. 1987;  48 197-200
• 4 Coryell W. The treatment of psychotic depression.  J Clin Psychiat. 1998;  59 (Suppl. 1) 22-29
• 5 Eap C B, Bender S, Gastpar M, Fischer W, Haarmann C, Powell K. et al . Steady-state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.  Ther Drug Monit. 2000;  22 209-214
• 6 Eap C B, Koeb L, Holsboer-Trachsler E, Baumann P. Plasma levels of trimipramine and metabolites in four patients: determination of the enantiomer concentrations of the hydroxy metabolites.  Ther Drug Monit. 1992;  14 380-385
• 7 Gross G, Xin X, Gastpar M. Trimipramine - Pharmacological reevaluation and comparison with clozapine.  Neuropharmacology. 1991;  30 1159-1166
• 8 Hamilton M. A rating scale for depression.  J Neurol Neurosurg Psychiat. 1960;  23 56-62
• 9 Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, Hobi V. Sleep deprivation and bright light as potential augmenters of antidepressant drug treatment-neurobiological and psychometric assessment of course.  J Psychiatr Res. 1994;  28 381-399
• 10 Holsboer F. Neuroendocrinology of affective disorders. In Bloom FE, Kupfer DJ (eds) Neuropsychopharmacology. 4^th Generation of Progress. New York; Raven Press 1995: p. 957-970
• 11 Holsboer F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety.  J Psychiatr Res. 1999;  33 181-214
• 12 Holsboer F. The corticosteroid receptor hypothesis of depression.  Neuropsychopharmacology. 2000;  23 477-501
• 13 Holsboer F, Barden N. Antidepressants and hypothalamic-pituitary-adrenocortical regulation.  Endocr Rev. 1996;  17 187-205
• 14 Laakmann G. Psychopharmakoendokrinologie und Depressionsforschung. Monographien aus dem Gesamtgebiete der Psychiatrie. 46: Berlin, Heidelberg, New York: Springer;
• 15 Modell S, Lauder C J, Schreiber W, Huber J, Krieg J C, Holsboer F. Hormonal response pattern in the combinded Dex-CRH test is stable over time in subjects at high familial risk for affective disorder.  Neuropsychopharmacology. 1998;  18 253-262
• 16 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change.  Br J Psychiatry. 1979;  134 382-389
• 17 Overall J E, Gorham D R. Brief Psychiatric Rating Scale. In Guy W (eds.) ECDEU assessment manual for psychopharmacology, revised. Rockville, Maryland, USA; National Institute of Mental Health 1976
• 18 Perry P J, Zeilmann C, Armdt S. Tricyclic antidepressant concentrations in plasma: an estimate of their sensitivity and specificity as a predictor of response.  J Clin Psychopharmacol. 1994;  14 230-240
• 19 Posener J A, DeBattista C, Williams G H, Kraemer H C, Kalezhan M, Schatzberg A F. 24-hour monitoring of cortisol and corticotropin secretion in psychotic and nonpsychotic major depression.  Arch Gen Psychiatry. 2000;  57 755-760
• 20 Reul J M, Labeur M S, Grigoriadis D E, De Souza E B, Holsboer F. Hypothalamic-pituitary-adrenocortical axis changes in the rat after long-term treatment with the reversible monoamine oxidase-A inhibitor moclobemide.  Neuroendocrinology. 1994;  60 509-519
• 21 Reul J M, Stec I, Söder M, Holsboer F. Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system.  Endocrinology. 1993;  133 312-320
• 22 Rothshild A J, Langlais P J, Schatzberg A F, Walsh F X, Cole J O, Bird E D. Dexamethasone increases plasma free dopamine in man.  J Psychiatr Res. 1984;  18 217-223
• 23 Rothschild A J, Samson J A, Bessette M P, Carter-Campbell J T. Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.  J Clin Psychiat. 1993;  54 338-342
• 24 Rothschild A J, Samson J A, Bond T C, Luciana M M, Schildkraut J J, Schatzbert A F. Hypothalamic-pituitary-adrenal axis activity and 1-year outcome in depression.  Biol Psychiatry. 1993;  34 392-400
• 25 Rudorfer M V, Hwu H G, Clayton P J. Dexamethasone suppression test in primary depression: significance of family history and psychosis.  Biol Psychiatry. 1982;  17 41-48
• 26 Schatzberg A F, Rothschild A J, Langlais P J, Bird E D, Cole J O. A corticosteroid/dopamine hypothesis for psychotic depression and related states.  J Psychiatr Res. 1985;  19 57-64
• 27 Sonntag A, Rothe B, Guldner J, Yassouridis A, Holsboer F, Steiger A. Trimipramine and imipramine exert different effects on the sleep EEG and on nocturnal hormone secretion during treatment of major depression.  Depression. 1996;  4 1-13
• 28 Spiker D G, Kupfer D J. Placebo response rates in psychotic and nonpsychotic depression.  J Affect Disord. 1988;  14 21-23
• 29 Spiker D G, Weiss J C, Dealy R S, Griffin S J, Hanin I, Neil J F. et al . The pharmacological treatment of delusional depression.  Am J Psychiatry. 1985;  142 430-436
• 30 Steiger A, Benkert O, Wöhrmann S, Steinseifer D, Holsboer F. Effects of trimipramine on sleep EEG, penile tumescence and nocturnal hormonal secretion. A long-term study in 3 normal controls.  Neuropsychobiology. 1989;  21 71-75
• 31 Steiger A, von Bardeleben U, Guldner J, Lauer C, Rothe B, Holsboer F. The sleep EEG and nocturnal hormonal secretion. Studies on changes during the course of depression and on effects of CNS-active drugs.  Prog Neuropsychopharmacol Biol Psychiatry. 1993;  17 125-137
• 32 Zanardi R, Franchini L, Gasperini M, Perez J, Smeraldi E. Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.  Am J Psychiatry. 1996;  153 1631-1633
• 33 Von Zerssen D. Self-rating scales for evaluation of patient’s subjective state in cross-sectional and longitudinal studies of psychopathology.  Arch Psychiatr Nervenkr. 1973;  217 299-314